(function(){var loadHandler=window['sl_{70F84434-E230-4897-A900-6C791B0E8453}'];loadHandler&&loadHandler(2, '<div id="spr0_52e6c868"><div id="spr1_52e6c868" class="kern slide"><img id="img4_52e6c868" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_52e6c868" class="kern slide"><img id="img0_52e6c868" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_52e6c868" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_52e6c868" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_52e6c868" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_52e6c868" style="left:657.715px;top:499.855px;"><img id="img2_52e6c868" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_52e6c868" style="left:0.563px;top:6.989px;"><div style="width:0px;"><span id="txt0_52e6c868" data-width="506.015625" style="left:106.888px;top:5.086px;">2016 CCS Lipid Guidelines Recommend:</span></div><div style="width:0px;"><span id="txt1_52e6c868" class="relpos" data-width="103.515625" style="left:83.738px;top:47.403px;">Beyond </span><span id="txt2_52e6c868" class="relpos" data-width="82.001953" style="left:83.733px;top:43.672px;">Statin</span><span id="txt3_52e6c868" class="relpos" data-width="367.375000" style="left:83.728px;top:47.403px;"> Drugs for ASCVD Prevention</span></div></div><div id="spr5_52e6c868" style="left:19.805px;top:164.544px;"><div style="width:0px;"><span id="txt4_52e6c868" data-width="189.472656" style="left:69.38px;top:6.231px;">TREATMENT TARGETS:</span></div></div><div id="spr6_52e6c868" style="left:3.349px;top:157.156px;"><div style="width:0px;"><span id="txt5_52e6c868" class="nokern relpos" data-width="16.417969" style="left:7.2px;top:4.715px;">1.</span><span id="txt6_52e6c868" class="relpos" data-width="628.851563" style="left:26.782px;top:4.715px;">We recommend ezetimibe as second-line therapy to lower LDL-C in</span></div><div style="width:0px;"><span id="txt7_52e6c868" data-width="655.242188" style="left:43.2px;top:33.515px;">patients with clinical cardiovascular disease if targets are not reached</span></div><div style="width:0px;"><span id="txt8_52e6c868" class="relpos" data-width="358.757813" style="left:43.2px;top:62.315px;">on maximally tolerated statin therapy. </span><span id="txt9_52e6c868" class="relpos" data-width="252.672653" style="left:43.195px;top:65.987px;">(Strong Recommendation, High</span></div><div style="width:0px;"><span id="txt10_52e6c868" data-width="143.102341" style="left:43.2px;top:90.857px;">Quality evidence)</span></div><div style="width:0px;"><span id="txt11_52e6c868" class="nokern relpos" data-width="16.417969" style="left:7.2px;top:115.322px;">2.</span><span id="txt12_52e6c868" class="relpos" data-width="575.484375" style="left:26.782px;top:115.322px;">We recommend that niacin not be added to statin therapy for CVD</span></div><div style="width:0px;"><span id="txt13_52e6c868" class="relpos" data-width="500.003906" style="left:43.2px;top:144.122px;">prevention in patients who have achieved LDL-C targets. </span><span id="txt14_52e6c868" class="relpos" data-width="60.446098" style="left:43.195px;top:147.956px;">(Strong</span></div><div style="width:0px;"><span id="txt15_52e6c868" data-width="311.149231" style="left:43.2px;top:172.819px;">Recommendation, High Quality Evidence)</span></div><div style="width:0px;"><span id="txt16_52e6c868" class="nokern relpos" data-width="16.417969" style="left:7.2px;top:196.922px;">3.</span><span id="txt17_52e6c868" class="relpos" data-width="619.242188" style="left:26.782px;top:196.922px;">We do not recommend the addition of fibrates to statin therapy for CVD</span></div><div style="width:0px;"><span id="txt18_52e6c868" class="relpos" data-width="553.628906" style="left:43.2px;top:225.722px;">event prevention in patients who have achieved LDL-C targets. </span><span id="txt19_52e6c868" class="relpos" data-width="60.446098" style="left:43.195px;top:229.556px;">(Strong</span></div><div style="width:0px;"><span id="txt20_52e6c868" class="relpos" data-width="302.955872" style="left:43.2px;top:254.448px;">recommendation, High Quality evidence)</span><span id="txt21_52e6c868" class="relpos" data-width="9.121094" style="left:43.195px;top:254.302px;">. </span><span id="txt22_52e6c868" class="relpos" data-width="184.469528" style="left:43.19px;top:254.448px;">Values and preferences:</span><span id="txt23_52e6c868" class="relpos" data-width="165.029297" style="left:43.185px;top:254.302px;"> In sub-group analysis,</span></div><div style="width:0px;"><span id="txt24_52e6c868" data-width="606.230469" style="left:43.2px;top:278.302px;">patients with elevated triglycerides and low HDL-C may benefit from fibrate therapy.</span></div></div><div id="spr7_52e6c868" style="left:210px;top:90.456px;"><img id="img3_52e6c868" src="data/img6.png" width="300" height="75" alt="Image result for canadian cardiovascular society"/></div><div id="spr8_52e6c868" style="left:3.349px;top:509.906px;"><div style="width:0px;"><span id="txt25_52e6c868" class="nokern" data-width="618.160156" style="left:9.321px;top:6.162px;">Anderson et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology 2016;32:1263-1282</span></div></div><div id="spr9_52e6c868" style="left:3.349px;top:509.906px;"><div style="width:0px;"><span id="txt26_52e6c868" class="nokern" data-width="618.160156" style="left:7.2px;top:4.041px;">Anderson et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology 2016;32:1263-1282</span></div></div></div></div>');})();